Delineation of Platelet Activation Pathway of Scutellarein Revealed Its Intracellular Target as Protein Kinase C

Biological and Pharmaceutical Bulletin

Volumn 39, Issue 2, 2016, Pages 181-191

  Tian, Xiaoxuan ^a,b   Chang, Lianying ^a,b,d   Ma, Guangyin ^a,b   Wang, Taiyi ^a,b   Lv, Ming ^a,b   Wang, Zhilong ^a,b   Chen, Liping ^a,b,e   Wang, Yuefei ^a,b   Gao, Xiumei ^a   Zhu, Yan ^a,b,c  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Tianjin International Joint Academy of Biotechnology and Medicine   (China)

^c TUFTS MEDICAL CENTER   (United States)

^d FIRST TEACHING HOSPITAL OF TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e Buchang Pharmaceutical Co Ltd   (China)

Author keywords

Antiplatelet; Cardiovascular; Dengzhanxixin (Erigeron breviscapus); Protein kinase C (PKC); Scutellarein; Traditional Chinese medicine (TCM)

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; SCUTELLAREIN; THROMBIN; APIGENIN; CALCIUM; CYCLIC AMP; FIBRINOGEN; G PROTEIN COUPLED RECEPTOR; ISOENZYME; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; INTRACELLULAR TRANSPORT; MALE; MOLECULAR DOCKING; NONHUMAN; RAT; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; AGONISTS; ANIMAL; CELL ADHESION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ERIGERON; GENETICS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THROMBOCYTE;

ANIMALS; APIGENIN; BLOOD PLATELETS; CALCIUM; CELL ADHESION; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ERIGERON; FIBRINOGEN; ISOENZYMES; MALE; MOLECULAR STRUCTURE; PLATELET ACTIVATION; PLATELET AGGREGATION; PROTEIN KINASE C BETA; PROTEIN KINASE C-ALPHA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84958954147     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00511     Document Type: Article

References (83)

1. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler. Thromb. Vasc. Biol., 30, 2341-2349 (2010).
2. Wang Y, Andrews M, Yang Y, Lang S, Jin JW, Cameron-Vendrig A, Zhu G, Reheman A, Ni H. Platelets in thrombosis and hemostasis: Old topic with new mechanisms. Cardiovasc. Hematol. Disord. Drug Targets, 12, 126-132 (2012).
3. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov., 9, 154-169 (2010).
4. Li XL, Li YQ, Yan WM, Li HY, Xu H, Zheng XX, Guo DW, Tang LK. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med., 70, 1039-1044 (2004).
5. Shen Z, Lei W, Duan L, Chen Z. Inhibitory effects of Erigeron breviscapus flavones on platelet aggregation and thrombosis. Natural Product Research and Development, 12, 22-25 (2000).
6. Niangui L, Fongzen L, Xinzun M. Effect of Erigeron breviscapus hand on hemorheology and microcirculation of acute cerebral infarction. Chinese Journal of Hemorheology, 3, (1998).
7. Ying W, Xiangliang Y, Hong L, Xiaoqiao T. Study on effects of Erigeron breviscapus extract on anticoagulation. Journal of Chinese Medicinal Materials, (2003).
8. Lei K, Huang X, Wu Q, Xie X, Yu L, Lu Y. The effects of breviscapine on platelet aggregation and intra-platelet free calcium. Acta Acad. Med. Zunyi, 2004, 11-13 (2004).
9. Guo C, Zhu Y, Weng Y, Wang S, Guan Y, Wei G, Yin Y, Xi M, Wen A. Therapeutic time window and underlying therapeutic mechanism of breviscapine injection against cerebral ischemia/reperfusion injury in rats. J. Ethnopharmacol., 151, 660-666 (2014).
10. Yang W, Cheng H, Xie Y, Yang H, Zhuang Y. Dengzhanxixin injection using character analysis in clinical based on real world HIS database. Zhongguo Zhong Yao Za Zhi, 37, 2718-2722 (2012).
11. Wang X, Xia H, Liu Y, Qiu F, Di X. Simultaneous determination of three glucuronide conjugates of scutellarein in rat plasma by LC-MS/MS for pharmacokinetic study of breviscapine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 965, 79-84 (2014).
12. Ju W, Chu J, Tan R, Xiong N. Study on metabolites of scutellarin in gastrointestinal tract by UPLC-MS/MS method. Chinese Journal of Clinical Pharmacology and Therapeutics, 292-295 (2006).
13. Ju W, Zhang J, Tan H, Jiang M, Chen W, Chen N. Determination of scutellarin in human plasma by LC-MS method and its clinical pharmacokinetics in Chinese healthy volunteers. Chinese Journal of Clinical Pharmacology and Therapeutics, 10, 298301 (2005).
14. Liu Q, Shi Y, Wang Y, Lu J, Cong W, Luo G, Wang Y. Metabolism profile of scutellarin in urine following oral administration to rats by ultra performance liquid chromatography coupled to time-offlight mass spectrometry. Talanta, 80, 84-91 (2009).
15. Che Q, Pan L, Chen Y, He H. Study on Pharmacokinetics of Scutellarein in Rats. Chinese Pharmaceutical Journal, 1418-1421 (2007).
16. Xu G. Inhibition of protein kinase C by scutellarein and its analogues. ACTA-ACADEMIAE MEDICINAE SHANGHAI, 20, 187-187 (1993).
17. Zhou J, Lei H, Chen Y, Li F, Ma C. Ventricular remodeling by scutellarein treatment in spontaneously hypertensive rats. Chinese Medical Journal, 115, 375-377 (2002).
18. Song Y, Zhang H, Ma J, Li C. Effects of scutellarein on thrombosis and hemorheology in rats. Chin. J. New Drugs, 20, 1446-1449 (2011).
19. Li W-y, Xu X-y, Li F-q. Chen Y-z, Ding M. The effects of scutellarein on platelet cytosolic free calcium concentration, platelet aggregation rate, and heart remodeling in rats. Chinese New Drugs Journal, 13, 220-223 (2004).
20. Stephens G, O'Luanaigh N, Reilly D, Harriott P, Walker B, Fitzgerald D, Moran N. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J. Biol. Chem., 273, 20317-20322 (1998).
21. Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS, Dauerman HL, French PA, Becker RC. Platelet biology and response to antiplatelet therapy in women: Implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J. Am. Coll. Cardiol., 59, 891-900 (2012).
22. Baldissera-Jr L, Monteiro PF, De Mello GC, Morganti RP, Antunes E. Platelet adhesion and intracellular calcium levels in antigenchallenged rats. Pulm. Pharmacol. Ther., 23, 327-333 (2010).
23. Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal. Biochem., 216, 444-450 (1994).
24. Bednar B, Condra C, Gould RJ, Connolly TM. Platelet aggregation monitored in a 96 well microplate reader is useful for evaluation of platelet agonists and antagonists. Thromb. Res., 77, 453-463 (1995).
25. Fratantoni JC, Poindexter BJ. Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies. Am. J. Clin. Pathol., 94, 613-617 (1990).
26. Moran N, Kiernan A, Dunne E, Edwards RJ, Shields DC, Kenny D. Monitoring modulators of platelet aggregation in a microtiter plate assay. Anal. Biochem., 357, 77-84 (2006).
27. Krishnamurthi S, Patel Y, Kakkar VV. Inhibition of agonist-induced platelet aggregation, Ca2+ mobilization and granule secretion by guanosine 5-[beta-thio]diphosphate and GDP in intact platelets. Evidence for an inhibitory mechanism unrelated to the inhibition of G-protein-GTP interaction. Biochem. J., 250, 209-214 (1988).
28. Garcia JG, Patterson C, Bahler C, Aschner J, Hart CM, English D. Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J. Cell. Physiol., 156, 541-549 (1993).
29. Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur. Heart J., 33, 2856-2864 (2012).
30. Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GV. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: Implications for the pathogenesis of Alzheimer's disease. J. Biol. Chem., 284, 18754-18766 (2009).
31. Zhou X, He P. Temporal and spatial correlation of platelet-activating factor-induced increases in endothelial [Ca2+]i, nitric oxide, and gap formation in intact venules. Am. J. Physiol. Heart Circ. Physiol., 301, H1788-H1797 (2011).
32. Ho H, Singh H, Heng S, Nero TL, Paule S, Parker MW, Johnson AT, Jiao GS, Nie G. Small molecule proprotein convertase inhibitors for inhibition of embryo implantation. PLoS ONE, 8, e81380 (2013).
33. Wright B, Gibson T, Spencer J, Lovegrove JA, Gibbins JM. Plateletmediated metabolism of the common dietary flavonoid, quercetin. PLoS ONE, 5, e9673 (2010).
34. Chai L, Guo H, Li H, Wang S, Wang YL, Shi F, Hu LM, Liu Y, Adah D. Scutellarin and caffeic acid ester fraction, active components of Dengzhanxixin injection, upregulate neurotrophins synthesis and release in hypoxia/reoxygenation rat astrocytes. J. Ethnopharmacol., 150, 100-107 (2013).
35. Lin LL, Liu AJ, Liu JG, Yu XH, Qin LP, Su DF. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J. Cardiovasc. Pharmacol., 50, 327-332 (2007).
36. Yiming L, Wei H, Aihua L, Fandian Z. Neuroprotective effects of breviscapine against apoptosis induced by transient focal cerebral ischaemia in rats. J. Pharm. Pharmacol., 60, 349-355 (2008).
37. Liu H, Yang X, Ren T, Feng Y, Xu H. Effects of Erigeron breviscapus ethanol extract on neuronal oxidative injury induced by superoxide radical. Fitoterapia, 76, 666-670 (2005).
38. Ju WZ, Zhao Y, Liu F, Wu T, Zhang J, Liu SJ, Zhou L, Dai GL, Xiong NN, Fang ZY. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomedicine, 22, 319-325 (2015).
39. Wang SX, Guo H, Hu LM, Liu YN, Wang YF, Kang LY, Gao XM. Caffeic acid ester fraction from Erigeron breviscapus inhibits microglial activation and provides neuroprotection. Chin. J. Integr. Med., 18, 437-444 (2012).
40. He M, Xue ZM, Li J, Zhou BQ. Breviscapine inhibits high glucoseinduced proliferation and migration of cultured vascular smooth muscle cells of rats via suppressing the ERK1/2 MAPK signaling pathway. Acta Pharmacol. Sin., 33, 606-614 (2012).
41. Ghosh N, Ghosh R, Bhat ZA, Mandal V, Bachar SC, Nima ND, Sunday OO, Mandal SC. Advances in herbal medicine for treatment of ischemic brain injury. Nat. Prod. Commun., 9, 1045-1055 (2014).
42. Zhu BH, Guan YY, He H, Lin MJ. Effects of scutellarein on diabetic rat aorta. Acta Pharmacol. Sin., 21, 353-356 (2000).
43. Shi X, Chen G, Liu X, Qiu Y, Yang S, Zhang Y, Fang X, Zhang C, Liu X. Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcoma in vivo. Int. J. Mol. Med., 35, 31-38 (2015).
44. Cheng CY, Hu CC, Yang HJ, Lee MC, Kao ES. Inhibitory effects of scutellarein on proliferation of human lung cancer A549 cells through ERK and NFkappaB mediated by the EGFR pathway. Chin. J. Physiol., 57, 182-187 (2014).
45. Yan S, Hong-mei Z, Jian-jian M, Chang-ling L. Effects of scutellarein on thrombosis and hemorheology in rats. Chinese Journal of New Drugs, 1446-1449 (2011).
46. Shattil SJ, Newman PJ. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood, 104, 1606-1615 (2004).
47. Rink TJ, Sage SO. Calcium signaling in human platelets. Annu. Rev. Physiol., 52, 431-449 (1990).
48. Strehl A, Munnix IC, Kuijpers MJ, Van Der Meijden PE, Cosemans JM, Feijge MA, Nieswandt B, Heemskerk JW. Dual role of platelet protein kinase C in thrombus formation: Stimulation of pro-aggregatory and suppression of procoagulant activity in platelets. J. Biol. Chem., 282, 7046-7055 (2007).
49. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J. Thromb. Haemost., 8, 454-462 (2010).
50. Navarro-Núñez L, Rivera J, Guerrero JA, Martinez C, Vicente V, Lozano ML. Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets. Br. J. Pharmacol., 158, 1548-1556 (2009).
51. Navarro-Núñez L, Lozano ML, Palomo M, Martinez C, Vicente V, Castillo J, Benavente-Garcia O, Diaz-Ricart M, Escolar G, Rivera J. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. J. Agric. Food Chem., 56, 2970-2976 (2008).
52. Fuentes E, Caballero J, Alarcon M, Rojas A, Palomo I. Chlorogenic acid inhibits human platelet activation and thrombus formation. PLoS ONE, 9, e90699 (2014).
53. Oh WJ, Endale M, Park SC, Cho JY, Rhee MH. Dual roles of quercetin in platelets: Phosphoinositide-3-kinase and MAP kinases inhibition, and cAMP-dependent vasodilator-stimulated phosphoprotein stimulation. Evid. Based Complement. Alternat. Med., 2012, 485262 (2012).
54. Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, Chin M, Onaya T. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur. J. Pharmacol., 212, 87-92 (1992).
55. Chang SS, Lee VS, Tseng YL, Chang KC, Chen KB, Chen YL, Li CY. Gallic acid attenuates platelet activation and platelet-leukocyte aggregation: Involving pathways of Akt and GSK3beta. Evid. Based Complement. Alternat. Med., 2012, 683872 (2012).
56. Kim SD, Lee YJ, Baik JS, Han JY, Lee CG, Heo K, Park YS, Kim JS, Ji HD, Park SI, Rhee MH, Yang K. Baicalein inhibits agonistand tumor cell-induced platelet aggregation while suppressing pulmonary tumor metastasis via cAMP-mediated VASP phosphorylation along with impaired MAPKs and PI3K-Akt activation. Biochem. Pharmacol., 92, 251-265 (2014).
57. Jin JL, Lee S, Lee YY, Kim JM, Heo JE, Yun-Choi HS. Platelet anti-aggregating triterpenoids from the leaves of Acanthopanax senticosus and the fruits of A. sessiliflorus. Planta Med., 70, 564-566 (2004).
58. Chang WC, Hsu FL. Inhibition of platelet activation and endothelial cell injury by polyphenolic compounds isolated from Lonicera japonica Thunb. Prostaglandins Leukot. Essent. Fatty Acids, 45, 307-312 (1992).
59. Satake T, Kamiya K, An Y, Oishi (nee Taka) T, Yamamoto J. The anti-thrombotic active constituents from Centella asiatica. Biol. Pharm. Bull., 30, 935-940 (2007).
60. Robbins RC. Flavones in citrus exhibit antiadhesive action on platelets. Int. J. Vitam. Nutr. Res., 58, 418-421 (1988).
61. Park JB. 5-Caffeoylquinic acid and caffeic acid orally administered suppress P-selectin expression on mouse platelets. J. Nutr. Biochem., 20, 800-805 (2009).
62. Gutierrez-Lugo MT, Deschamps JD, Holman TR, Suarez E, Timmermann BN. Lipoxygenase inhibition by anadanthoflavone, a new flavonoid from the aerial parts of Anadenanthera colubrina. Planta Med., 70, 263-265 (2004).
63. Kimura Y, Okuda H, Arichi S. Effects of baicalein on leukotriene biosynthesis and degranulation in human polymorphonuclear leukocytes. Biochim. Biophys. Acta, 922, 278-286 (1987).
64. Huang WH, Lee AR, Chien PY, Chou TC. Synthesis of baicalein derivatives as potential anti-aggregatory and anti-inflammatory agents. J. Pharm. Pharmacol., 57, 219-225 (2005).
65. Verma RP. A classical QSAR study on some platelet aggregation inhibitors. Mini Rev. Med. Chem., 6, 467-482 (2006).
66. Jin JL, Lee S, Lee YY, Kim JM, Heo JE, Yun-Choi HS. Platelet anti-aggregating triterpenoids from the leaves of Acanthopanax senticosus and the fruits of A. sessiliflorus. Planta Med., 70, 564-566 (2004).
67. Koleckar V, Brojerova E, Rehakova Z, Kubikova K, Cervenka F, Kuca K, Jun D, Hronek M, Opletalova V, Opletal L. In vitro antiplatelet activity of flavonoids from Leuzea carthamoides. Drug Chem. Toxicol., 31, 27-35 (2008).
68. Ling SK, Pisar MM, Man S. Platelet-activating factor (PAF) receptor binding antagonist activity of the methanol extracts and isolated flavonoids from Chromolaena odorata (L.) KING and ROBINSON. Biol. Pharm. Bull., 30, 1150-1152 (2007).
69. Sekiya K, Okuda H, Arichi S. Selective inhibition of platelet lipoxygenase by esculetin. Biochim. Biophys. Acta, 713, 68-72 (1982).
70. Kayahara H, Miao Z, Fujiwara G. Synthesis and biological activities of ferulic acid derivatives. Anticancer Res., 19 (5A), 3763-3768 (1999).
71. Chen I-S, Lin Y-C, Tsai I-L, Teng C-M, Ko F-N, Ishikawa T, Ishii H. Coumarins and anti-platelet aggregation constituents from Zanthoxylum schinifolium. Phytochemistry, 39, 1091-1097 (1995).
72. Dorsch W, Bittinger M, Kaas A, Müller A, Kreher B, Wagner H. Antiasthmatic effects of Galphimia glauca, gallic acid, and related compounds prevent allergen-and platelet-activating factor-induced bronchial obstruction as well as bronchial hyperreactivity in guinea pigs. Int. Arch. Allergy Immunol., 97, 1-7 (1992).
73. Osman HE, Maalej N, Shanmuganayagam D, Folts JD. Grape juice but not orange or grapefruit juice inhibits platelet activity in dogs and monkeys (Macaca fasciularis). J. Nutr., 128, 2307-2312 (1998).
74. Lin CN, Kuo SH, Chung MI, Ko FN, Teng CM. A new flavone Cglycoside and antiplatelet and vasorelaxing flavones from Gentiana arisanensis. J. Nat. Prod., 60, 851-853 (1997).
75. Dell'Agli M, Maschi O, Galli GV, Fagnani R, Dal Cero E, Caruso D, Bosisio E. Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase. Br. J. Nutr., 99, 945-951 (2008).
76. Corvazier E, Maclouf J. Interference of some flavonoids and nonsteroidal anti-inflammatory drugs with oxidative metabolism of arachidonic acid by human platelets and neutrophils. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 835, 315-321 (1985).
77. Facino RM, Carini M, Franzoi L, Pirola O, Bosisio E. Phytochemical characterization and radical scavenger activity of flavonoids from Helichrysum italicum G. Don (Compositae). Pharmacological Research: The Official Journal of the Italian Pharmacological Society, 22, 709-721 (1990).
78. Beretz A, Stierle A, Anton R, Cazenave JP. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Biochem. Pharmacol., 31, 3597-3600 (1982).
79. Okada Y, Miyauchi N, Suzuki K, Kobayashi T, Tsutsui C, Mayuzumi K, Nishibe S, Okuyama T. Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Chem. Pharm. Bull., 43, 1385-1387 (1995).
80. Gao R, Zhu BH, Tang SB, Wang JF, Ren J. Scutellarein inhibits hypoxia-and moderately-high glucose-induced proliferation and VEGF expression in human retinal endothelial cells. Acta Pharmacol. Sin., 29, 707-712 (2008).
81. Zhu B-H, Guan Y-Y, He H, Lin M-J. Effects of scutellarein on diabetic rat aorta. Acta Pharmacol. Sin., 21, 353-356 (2000).
82. Thijssen MA, Hornstra G, Mensink RP. Stearic, oleic, and linoleic acids have comparable effects on markers of thrombotic tendency in healthy human subjects. J. Nutr., 135, 2805-2811 (2005).
83. Wu YC, Chang GY, Ko FN, Teng CM. Bioactive constitutents from the stems of Annona montana. Planta Med., 61, 146-149 (1995).